Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diphereline versus Microrelin for ovarian suppression in premenopausal breast cancer
IRCT20201227049847N1Phase 3Completed
- Sponsor
- Homa Pharmed
- Start
- Apr 2019
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label trial of triptorelin in breast cancer (3 arms), sponsored by Homa Pharmed. Primary endpoints: Change in serum estradiol level over one year and Ability to induce menopause. Started Apr 2019; status: completed.
02
Drugs
triptorelin
03
Conditions
breast cancer
Beyond the preview
Go deeper on IRCT20201227049847N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20201227049847N1.